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INTRODUCTION
The tripeptide L-prolyl-L-leucyl-glycinamide (PLG), also known as melanocyte stimulating hormone release-inhibiting factor, has been demonstrated to possess a variety of pharmacological activities in the central nervous system (Drucker et al., 1994; Reed et al., 1994; Srivastava et al., 1988) . A series of earlier clinical studies showed that this tripeptide possessed substantial therapeutic activity in Parkinson's disease, 3,4-dihydroxy-L-phenylalanine-induced dyskinesia, antipsychotic drug-induced tardive dyskinesia and depression (Barbeau et al., 1978; Ehrensing et al., 1974 Ehrensing et al., ,1994 . However, PLG's therapeutic activity still needs much improvement in terms of its efficacy and potency. For example, Barbeau et al. (1978) , has previously shown that PLG improved the signs of Parkinson's disease in some patients, yet, failed to detect significant improvement in other patients. However, these authors did report consistent clinical trends, suggesting that further work on this tripeptide would be beneficial.
Currently, little is known about the mechanistic action of PLG, thus, in view of reports that PLG has demonstrated potential therapeutic effects in many CNS disorders (Mishra et al., 1983 (Mishra et al., , 1986 , it would be of interest to study the mechanistic manner in which PLG modulates central DA receptors in order to produce an effective and potent drug for people suffering from such disorders. PLG has also been shown to enhance the binding of various agonists such as apomorphine, 2-amino-6,7-dihydroxy-1,2,3,4,-tetrahydronaphthalene (ADTN) and Npropylnorapomorphine (NPA) to striatal DA receptors, whereas antagonist binding (haloperidol and spiperone) was unaffected (Bhargava,1983; Srivastava et al., 1988) . Moreover, PLG and its peptidomimetic analogues have been shown to modulate the affinity states of DA receptors possibly by enhancing its interaction with guanine nucleotide binding proteins (G-protein) (Costain et al., 1997; Srivastava et al., 1988) .
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Previous studies using bovine brain synaptosomal membrane fractions showed that PLG and its peptidomimetic analogues primarily modulate agonist binding to DA D 2 receptors . Brain tissue, however, contains a heterogeneous population of various DA receptor subtypes; therefore, it has not been possible to study the interaction of PLG with individual DA receptors using striatal membranes. Therefore, the present study was undertaken to establish specific DA receptor modulation by PLG and its potent peptidomimetic analogue, PAOPA (see Figure 1) , and to further determine whether the coupling of DA receptors to the Gprotein is required for such a modulatory effect. To execute this study, human neuroblastoma SH-SY5Y cells were transfected with the cDNA of specific DA receptor subtypes, thus generating stably expressing cell lines. This cell line was used for the following reasons: (i) it is a neuronal cell line that has been shown to display a high rate of DA receptor subtype expression (pmoles/mg protein) upon transfection (Nair et al., 1996; Hillion et al., 2002) ; (ii) these cells synthesize and release DA, as well as housing tyrosine hydroxylase and other related enzymes; (iii) various G proteins, as well as adenylyl cyclase, phospholipase, GTPase activity, PKA, and PKC are present in this cell line (Kazmi and Mishra 1989; Lambert and Nahorski,1990) . Lastly, although this cell line does not express DA receptors, it does express α 2 adrenergic, opiate (Kazmi and Mishra, 1987; 1989) , NMDA (Nair et al., 1996) , adenosine A 2 (Salim et al., 2000) and muscarinic receptors (Jope and Song, 1997 
synthesized as described previously (Yu et al., 1988) . Suramin was obtained from TocrisCookson (Ellisville, MO), while ascorbic acid was purchased from BDH Inc. (Toronto, ON).
Cell Culture and Gene Transfection
Human DA D 2L receptor cDNA was subcloned into the mammalian expression vector pRC/RSV (Invitrogen, USA) whereas human D 4 (cDNA-genomic hybrid, Van Tol et al., 1992) , D 2S , and D 1 receptor cDNAs were cloned into pCD-PS expression vectors (Invitrogen, USA). DNA was prepared using the Flexiprep plasmid isolation kit (Pharmacia, USA). Human neuroblastoma SH-SY5Y cells were grown at 37°C under 5% CO 2 / 95% air in RPMI media supplemented with 10% fetal calf serum, 1 mM glutamine, 50 U ml -1 penicillin and 50 U ml -1 streptomycin.
Transfection of cells with respective cDNA was performed with 10 µg of DNA to 3x10 7 cells as previously described by Nair et al (1996) . Cells were selected with geneticin
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Membrane Preparation and Receptor Binding Assays
The SH-SY5Y cells, stably expressing cloned human DA receptors, were grown to confluency and membranes were prepared as previously described (Nair et al., 1996) . The DA receptor agonist binding assays were carried out as previously described (Nair et al., 1996; . The assay buffer contained 50 mM tris (hydroxymethyl) aminomethane hydrochloric acid (Tris-HCl), 5 mM potassium chloride (KCl), 4 mM magnesium chloride (MgCl 2 ), 1 mM ethylenediaminetetraacetic acid (EDTA) and 120 mM sodium chloride (NaCl) (pH 7.6) with 100 µg of membrane protein in a total volume of 1 ml. 
Data Analysis
The data were analysed using GraphPad Prism software (version 4.1) (San Diego, California). obtained from the competition curves were converted to Ki values (inhibitory constant) using the Cheng and Prusoff equation (Cheng and Prusoff, 1973) . The data for Scatchard analysis were analyzed by non-linear regression using GraphPad and t-tests were used to compare differences among values between the experiments. Dose response curves were analyzed by one-way repeated measures of analysis of variance (ANOVA) using GraphPad Prism software, followed
by Newman-Keuls post-hoc test. The multiple comparison procedure used is indicated in the appropriate figure legend.
This article has not been copyedited and formatted. The final version may differ from this version. (Haran and Kastin, 1986; Costain et al., 1999; Mishra et al., 1997) and human clinical studies utilizing PLG (Drucker et al., 1994; Ehrensing et al., 1994) . In comparison to PLG, PAOPA displayed similar efficacy and ranged from being 10 to 1000 times more potent.
PLG and PAOPA increase [ This article has not been copyedited and formatted. The final version may differ from this version. (Bhargava, 1983; Chiu et al., 1981a; Mishra et al., 1990; Srivastava et al., 1988 In the PLG-treated D 2L receptor membranes, there was a leftward shift in the competition curve with an almost 3-fold decrease in K i for the high-affinity agonist binding site without any significant change in the K i for the low-affinity site. The ratio of high-to low-affinity sites in the PLG-treated membranes significantly increased from 1.12 (control) to 2.70 (Table 1 ).
The non-hydrolyzable analogue of GTP, Gpp(NH)p, caused a significant rightward shift in the competition curve for the D 2L receptor; this decreased the proportion of high-affinity binding sites to 18% with a K i of 0.15 nM. However, the conversion of the high-to low-affinity state was significantly attenuated by PLG. For example, the percentage of receptors in the highaffinity state was 34% with a K i of 0.040 nM in the PLG-treated membranes (Table 1 ). Yet, the affinity of the receptors remaining in the low-affinity state was unaffected (Table 1) . PAOPA demonstrated similar results to PLG (Table 2 ), yet, PAOPA was almost 1000-times more potent than PLG. as an antagonist and BHT-920 as the agonist, displayed a high-affinity and low-affinity state of agonist binding as previously reported in this cell line (Kazmi and Mishra, 1989 
PLG does not
Effect of Suramin on PLG induced increase in agonist binding
To establish whether PLG and PAOPA display modulatory effects on agonist binding to D 2 receptors in the absence of G-protein coupling, we investigated agonist binding in the absence and presence of suramin. Suramin is a polysulfonated naphthylurea and is considered to uncouple the receptor from the G-protein that results in decreased high-affinity agonist binding (Chung and Kermode, 2004; Nakata, 2003; Nickolls and Strange, 2003) . Both PLG and PAOPA, as shown in Figure 8 , were unable to modulate 16 treated with suramin and DA, but had no effect on the membranes treated with suramin alone.
Furthermore, to establish whether this lack of PLG modulation is due to a direct competition with suramin, a competition experiment was performed. As indicated in Figure 9 , the competition curve revealed that PLG does not compete with suramin for the receptor binding site.
DISCUSSION
The main findings of the present paper are first that both PLG and a conformationally constrained analogue (see Figure 1) receptors clearly reveals that the effect of PLG and PAOPA are dose-dependent with a maximal effect at 0.1 to 1.0 µM for PLG, and 0.001 to 0.1 µM for PAOPA. This dose response corroborates the phenomenon of a "therapeutic window" in which the pharmacological response for PLG can be elicited in animal models (Costain et al., 1999; Drucker et al., 1994; Sharma et al., 2003) and human clinical trials (reviewed by Mishra et al., 1986 Table 1 and 2), demonstrates an increased interaction between DA D 2 receptors and G-proteins. PLG was unable to increase agonist binding in the presence of suramin which uncouples the receptor/Gprotein complex; this suggests that PLG will only interact with D 2 receptors when they are coupled to the G-protein α−βγ subunits. However, the antagonistic effect of suramin on Gproteins can be reversed by the addition of agonist (Beindl et al., 1996) . In this case, the increased concentration of DA (100 µΜ) reversed the inhibitory effect of suramin because the agonist-liganded receptor competes with suramin for binding to the G-protein. Increasing the number of active receptors in the membrane by increasing agonist occupancy can overcome the inhibitory effect of suramin on the receptor/G-protein complex (Beindl et al., 1996) .
Additionally, the suggestion that PLG requires the receptor/G-protein complex may be part of (Filteau et al., 1999; McAllister et al., 1993) . It is also possible that PLG cannot modulate the D 3 receptor for reasons similar to that of GTP; further research is required to explore this possibility.
Previous studies have utilized bovine striatal membranes, which contains a heterogeneous population of DA receptors, as a means of testing the action of PLG on the DA receptor.
However, since the mechanism of the interaction between PLG and the DA receptor is still not clear, we have attempted to study this interaction in cultures stably transfected with individual DA receptor subtypes, which provided a model based analysis/interpretation of PLG's modulatory effect. This model facilitated specific attention to binding parameters as well as experimental manipulation to identify the role of high vs. low affinity and G-protein coupling.
Additionally, the importance of the D 2L receptor/G-protein complex is indicative of the possible site of interaction with PLG by which this endogenous neuropeptide may be modulating and increasing the number and affinity of the D 2L receptors in the high affinity state. We suggest a mechanism which proposes that PLG causes a conformational change in the receptor, presumably involving a putative PLG binding site on the D 2 receptor (Chiu et al., 1983a, b) ; this would lead to an increased association of the receptor with the G-protein (G i ) by adjusting the equilibrium between the receptor, G-protein and receptor/G-protein complex (Costain et al., 1997) . Such a mechanism would explain the enhancement of high-affinity agonist binding and the effect of PLG opposite to that of Gpp(NH)p.
This article has not been copyedited and formatted. The final version may differ from this version. to D 2 receptors, perhaps in an allosteric manner. However, unlike zinc or amilorides, PLG requires the D 2 receptor to be coupled to the G-protein and therefore, the molecular mechanisms of allosteric modulation for PLG are more distinct than other modulators. The simplest mechanism that describes an allosteric interaction between two ligands binding at distinct sites on a receptor is referred to as the ternary complex model (TCM) (Kenakin, 2004) . In this model This article has not been copyedited and formatted. The final version may differ from this version. 
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